Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy

BACKGROUND: Adalimumab is approved for use in patients with moderate to severe Crohn's disease (CD) or ulcerative colitis (UC) who have not achieved disease control with conventional therapies including corticosteroids and/or immunomodulators (IMM). AIM: To analyse six studies that examined eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombel, J.‐F., Jharap, B., Sandborn, W. J., Feagan, B., Peyrin‐Biroulet, L., Eichner, S. F., Robinson, A. M., Mostafa, N. M., Zhou, Q., Thakkar, R. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Immunomodulators and Adalimumab for IBD
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5157781/
https://www.ncbi.nlm.nih.gov/pubmed/27883215
http://dx.doi.org/10.1111/apt.13838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5157781/
https://www.ncbi.nlm.nih.gov/pubmed/27883215
http://dx.doi.org/10.1111/apt.13838

Ejemplares similares